Progyny (NASDAQ:PGNY) Updates FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.830-1.950 for the period, compared to the consensus earnings per share estimate of 1.550. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q1 2026 guidance to 0.420-0.450 EPS.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded up $0.92 during trading hours on Thursday, reaching $22.25. The stock had a trading volume of 1,852,843 shares, compared to its average volume of 1,439,322. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 35.32, a P/E/G ratio of 1.31 and a beta of 0.96. The firm’s 50 day moving average is $24.16 and its 200-day moving average is $23.14. Progyny has a 1 year low of $17.98 and a 1 year high of $28.75.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.24). Progyny had a net margin of 4.46% and a return on equity of 10.71%. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Analysts forecast that Progyny will post 0.6 EPS for the current year.

Analyst Upgrades and Downgrades

PGNY has been the subject of a number of research analyst reports. BTIG Research reaffirmed a “buy” rating on shares of Progyny in a report on Wednesday, January 21st. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Citigroup upgraded shares of Progyny to an “outperform” rating in a report on Tuesday, January 20th. JPMorgan Chase & Co. set a $35.00 price target on shares of Progyny in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group boosted their price target on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and a consensus price target of $29.80.

More Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 revenue beat and growth — Progyny reported Q4 revenue of $318.4 million, a 6.7% increase for the quarter and part of the company’s tenth consecutive year of revenue growth. Q4 results press release
• Positive Sentiment: FY‑2026 EPS guidance raised — Management set FY‑2026 EPS guidance at $1.83–$1.95, well above street consensus (~$1.55), suggesting improved profitability expectations. Guidance details
• Positive Sentiment: Strong cash generation and buybacks — Progyny reported record full‑year operating cash flow ($210.2M) and has repurchased ~6.5 million shares under its recent authorization, which supports EPS and shareholder value. Cash flow & buybacks
• Neutral Sentiment: Q1 EPS guidance above consensus but revenue guide below — Progyny gave Q1‑2026 EPS guidance of $0.420–$0.450 (above the $0.39 consensus) while issuing revenue guidance (~$319M–$332M) below the ~$344.9M street estimate, a mixed near-term outlook that tempers the FY optimism. Q1 guidance article
• Neutral Sentiment: Analyst commentary and valuation checks — Coverage pieces and previews are assessing retention strength, growth initiatives and whether recent share-price weakness presents a valuation opportunity; these conversations may influence positioning but are not immediate catalysts. Analyst preview
• Negative Sentiment: Q4 EPS miss — Progyny reported GAAP EPS of $0.14 for Q4, missing the ~$0.38 consensus by $0.24, which explains part of the stock’s intra‑day mixed reaction despite the revenue beat. Earnings snapshot
• Negative Sentiment: Rising short interest — Short interest jumped ~41% in February to >4.0M shares (≈5.1% of float), increasing downside pressure and the potential for sharper moves on negative headlines. (Short-interest data reported Feb 25.)

Institutional Investors Weigh In On Progyny

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada increased its position in Progyny by 384.8% in the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the period. Amundi lifted its position in Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after acquiring an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares during the last quarter. Invesco Ltd. grew its stake in shares of Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares during the last quarter. Finally, Walleye Capital LLC increased its holdings in shares of Progyny by 6.9% in the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after purchasing an additional 780 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.